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Abstract
This study aimed to investigate the anticandidal and antibiofilm activity of Artocarpus lakoocha extract against
various Candida. Anticandidal activity of A. lakoocha extract was determined using an agar well diffusion method. Minimum
inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) were assessed using a method of the Clinical
and Laboratory Standards Institute. A time kill assay was also performed. Antibiofilm activity was investigated using a 3-[4, 5-
dimethyl-2-thiazolyl]-2, 5-diphenyl-2H-tetrazolium-bromide (MTT) assay. The extract was found to be effective against all
tested Candida strains with MIC ranging from 0.05 to 3.12 mg/ml and MFC ranging from 0.10 to 25 mg/ml. The killing activity
depended on the time and concentrations of the extract. A. lakoocha extract acts as a potent antibiofilm agent with dual
actions, preventing and eradicating the biofilm. Results suggest that A. lakoocha extract is a potential source of natural
anticandidal agent, which may be useful for prevention or treatment of candidiasis.
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1. Introduction
There has been a significant increase in incidence of
infections  caused  by  Candida  spp.  (candidiasis),  mainly
due to the rise of the AIDS epidemic, an increasingly aged
population, higher numbers of immunocompromised patients,
the more widespread use of indwelling medical devices, and
the  use  of  broad  spectrum  antifungal  drugs.  Candida
albicans  is  the  main  cause  of  candidiasis,  however,  non-
C. albicans  (NCAC)  species  such  as  C.  dubliniensis,  C.
tropicalis,  C. glabrata  and  C. krusei  are  now  frequently
reported as human pathogens  (Moran et al., 2002).
The pathogenesis of candidiasis is facilitated by a
number of factors including the ability to adhere to medical
devices  and/or  host  cells  and  to  form  biofilms.  Biofilm
formation is an important virulence factor for a number of
Candida species, as it confers significant resistance to anti-
fungal  therapy  by  limiting  the  penetration  of  substances
through the matrix and protecting cells from host immune
responses (O’Toole et al., 2000; Kojic and Darouiche, 2004;
Kuhn et al., 2002; Li et al., 2012). It has been demonstrated
that biofilms formed by C. albicans and/or NCAC strains
have been associated with higher morbidity and mortality
rates compared with strains unable to form biofilms (Kuma-
moto, 2002).
Artocarpus lakoocha extract has been reported to
contain antibacterial activity against a wide range of bacteria
including  Mycobacterium  tuberculosis  H37Ra,  Bacillus
subtilis, B. pumilus, Proteus mirabilis, Shigella soneii and
Escherichia coli (Pandey et al., 2009; Puntumchai et al.,
2004).  A. lakoocha  is  a  valuable  tropical  tree  species
belonging  to  the  Moraceae  family;  commonly  found  in
tropical  areas  such  as  India  and  Thailand.  The  major
constituent of A. lakoocha bark extract is oxyresveratrol,
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(2,  4,  3,5-tetrahydroxystilbene),  which  has  also  been
reported  to possess in vitro anti-virus activity (anti-herpes
simplex virus (HSV), anti-varicella zoster virus) (Chuanasa
et al., 2008; Docherty et al., 2006; Likhitwitayawuid et al.,
2005; Sasivimolphan et al., 2009; Sritulaluk et al., 1998).
Another study suggested that oxyresveratrol was neuro-
protective  and  inhibited  apoptotic  cell  death  in  transient
ischemia  in  a  rat  model  (Andrabi  et  al.,  2004).  Due  to  its
reported  potent  tyrosinase  inhibitory  and  antioxidant
activities (Sritulaluk et al., 1998; Kim et al., 2002), the material
has potential application as a novel skin whitening agent in
cosmetic preparations (Tengamnuay et al., 2006). Most
studies have reported its antiviral and antibacterial activities;
however,  data regarding  the  antifungal  capability  of  A.
lakoocha extract has been limited.
The  aim  of  this  study  was  to  investigate  the  anti-
candidal  and  antibiofilm  activity  of  A. lakoocha  extract
against various Candida spp. via an in vitro study.
2. Materials and Methods
2.1 Preparation of A. lakoocha stem bark extract
The extract of A. lakoocha was obtained by boiling
small  pieces  of  stem  bark  in  water.  After  removing  the
remaining wood fragments and other insoluble residues, the
aqueous extract was dried to give a yellow-brown powder for
use in this study. The content of oxyresveratrol in the dried
extract  was  determined  to  be >80%  (w/w)  by  using  high
performance  liquid  chromatography.  A  10%  (w/v)  stock
solution of A.lakoocha extract was prepared in 10% (v/v)
dimethyl sulfoxide (DMSO, Merck) for use in this study.
2.2 Candida strains and growth conditions
The  tested  Candida  strains  included  Candida
albicans  ATCC  90028,  Candida  albicans  ATCC  10231,
Candida  dubliniensis  MYA-577,  Candida  dubliniensis
MYA-646, Candida glabrata ATCC 66032, Candida glabrata
ATCC 90030, Candida krusei ATCC 34135, Candida krusei
ATCC 6258, Candida tropicalis ATCC 66029, Candida
tropicalis ATCC 750, and Candida tropicalis ATCC 13803.
All strains were cultured on Sabouraud Dextrose Agar (SDA;
Difco Laboratories, Detroit, Michigan) aerobically at 37°C
for 24 h.
2.3 Anticandidal assay
2.3.1  Agar well diffusion assay
The broth culture of each tested strain (approximately
10
7 CFU/ml) was mixed thoroughly with the sterile SDA (20
ml), and then poured into a plate with 6-mm diameter metal
cups. The metal cups were removed after the medium set, and
then the wells were added with 100 µl of 10% A. lakoocha
extract, while 10% (w/v) DMSO was used as the negative
control and 0.1% (w/v) CHX was used as the positive control.
Plates were incubated at 37°C for 24 h. The antifungal activity
was evaluated by measuring inhibition zone diameters in
millimeters. Duplicates were maintained and the experiment
was repeated thrice.
2.3.2  Broth microdilution assay
The minimal inhibitory concentration (MIC) of A.
lakoocha extract against each tested strain was determined
by broth microdilution method (NCCLS, 2002). Briefly, two-
fold serial dilutions of A. lakoocha extract were prepared
with SDB at a total volume of 100 µl per well in 96-well micro-
titer plates. The final concentrations of A. lakoocha extract
ranged from 0.02 to 25.00 mg/ml. The microtiter plate wells
were inoculated with 100 µl of each tested strain at the final
concentration of 1×10
3 CFU/ml, and incubated at 37°C
 for
24  h. 
 The  negative  control  consisted  of  SDB  broth  and
Candida suspension without the agent, and the blank control
contained  only  the  medium.  The  MIC  was  defined  as  the
lowest  concentration  of  the  test  agent  that  completely  in-
hibited growth in comparison with the negative control. All
experiments were performed in triplicate.
The  minimal  fungicidal  concentration  (MFC)  was
defined as the lowest concentration in a well that did not allow
visible growth when 10 µl of the well content was plated on
agar and grown for 24 h at 37°C.
2.4 Killing kinetics assay
Candidal activity of A. lakoocha extract was studied
using a time-kill kinetic method. Growing cultures (10
6 CFU/
ml) of each  representative  strain,  C. albicans  ATCC  90028,
C. tropicalis ATCC 66029 and C. dubliniensis MYA-577 were
added to SDB and were exposed to 1×, 2× and 4× the MIC of
A. lakoocha extract. Samples were taken for colony counts at
0, 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h. The viable counts were
determined using the serial dilution method after incubation
at 37°C for 24 h. Each experiment was performed three times
to confirm the results. Chlorhexidine (CHX, 0.1% (w/v)) and
extract free were used as the positive and negative controls,
respectively.
2.5 Antibiofilm assay
2.5.1  Inhibition of biofilm formation
The effect of A. lakoocha extract on biofilm formation
of each representative strain, C. albicans ATCC 90028, C.
tropicalis ATCC 66029 and C. dubliniensis MYA-577 was
examined using the modified microdilution method (Tawee-
chaisupapong et al., 2010; Wu et al., 2013) . Briefly, two-fold
serial diluted concentrations (0.02-25.0 mg/ml) of A. lakoocha
extract were made in a flat-bottom 96-well microtiter plate.
The CHX (0.1%, w/v), PBS and the medium alone were used
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An equal volume of the tested strains (1×10
6 CFU/ml) was
added  and  mixed  with  the  agent,  except  in  the  well  with
medium alone (the blank control). Following incubation at
37°C for 24 h, supernatants were discarded and washed 3
times with PBS. Biofilm formation was quantified using a 3-
[4, 5-dimethyl-2-thiazolyl]-2, 5-diphenyl-2H-tetrazolium-
bromide (MTT) assay. After washing, 100 µl PBS with 0.5%
(w/v) MTT (Sigma-Aldrich, USA) solution was added and
allowed to incubate for 3 h at 37°C. The MTT solution was
replaced with 100 l DMSO and allowed to incubate for 15
min at room temperature. The number of surviving cells was
determined by measuring their ability to reduce the yellow
tetrazolium  salt  to  a  purple  formazan  product  at  570  nm.
Higher OD values indicate an increased number of surviving
Candida in the biofilm. Percentage inhibition was calculated
using this equation: [1-(A570 of the test/A570 of the non-
treated control)] ×100%. The biofilm inhibitory concentra-
tions (MBIC50 and MBIC90) were defined as the concentra-
tions that showed 50% and 90% inhibition of biofilm forma-
tion. All experiments were performed in triplicate.
2.5.2  Eradication of biofilm formation
The antimicrobial activity of A. lakoocha extract in
the biofilm was also examined using the minimum biofilm
eradication  concentration  (MBEC)  assay  (Brambilla  et  al.,
2009; Wu et al., 2013). Briefly, 200 µl (10
6 CFU/ml) of each
representative strain, C. albicans ATCC 90028, C. tropicalis
ATCC 66029 and C. dubliniensis MYA-577 was inoculated
into each well of the flat-bottom 96-well microtiter plate and
incubated  for  24  h  at  37°C.  After  biofilm  formation,  the
medium was then blotted out and the well carefully washed
three times with sterile PBS in order to remove non-adherent
cells. A. lakoocha extract was then added to the biofilms in
two-fold serial dilutions (0.02-25 mg/ml) and incubated for
24 h at 37°C. At the end-point of the treatment of the biofilms
with A. lakoocha extract, the adherent Candida was washed
three  times  with  sterile  PBS.  The  numbers  of  surviving
Candida were determined by a MTT assay. The MBEC value
was defined as the concentrations that showed 50% and
90% eradication of Candida in the biofilm. The 0.1% (w/v)
CHX, PBS and the medium alone were used as the positive,
non-treated and blank controls, respectively.  The experiments
were performed in triplicate.
2.6 Statistical analysis
The data were expressed as mean and standard devia-
tion (SD) by computational analysis from the three experi-
ments with duplicate independent experiments. Data from
biofilm  assay  were  analyzed  statistically  using  Mann-
Whitney  U  test.  Differences  were  considered  statistically
significant at P<0.05.
3. Results
The  anticandidal  activity  of  A. lakoocha  extract
was  evaluated  using  an  agar  well  diffusion  assay,  which
demonstrated that all tested strains were susceptible to A.
lakoocha extract with  variable  degrees  of  inhibition  zones
(Table  1). An example of an inhibition zone of A. lakoocha
extract  is  shown  in  Figure  1;  the  vehicle  control  (10%
DMSO) did not affect Candida growth. The MIC and MFC
of A. lakoocha extract as evaluated by a microdilution assay
are shown in Table 1. A. lakoocha extract exhibited anti-
candidal activity against most tested Candida strains with
MICs ranging from 0.05 to 3.12 mg/ml and MFCs ranging
from 0.10 to 25.00 mg/ml (Table 1).
Table 1. Antimicrobial activity of A. lakoocha extract against Candida spp.
Concentration of  A. lakoocha
extract (mg/ml)
    Stains of Candida spp.
MIC
a MFC
b
C. albicans ATCC 90028 20 ±0.13 0.78 1.56
C. albicans ATCC 10231 15 ±0.14 1.56 3.12
C. dubliniensis  MYA-577 15 ±0.21 0.78 1.56
C. dubliniensis  MYA-646 20 ±0.15 0.78 1.56
C. glabrata  ATCC 66032 20 ±0.13 1.56 25.00
C. glabrata  ATCC 90030 18 ±0.06 1.56 12.50
C. krusei  ATCC 34135 13 ±0.06 3.12 25.00
C. krusei  ATCC 6258 14 ±0.10 3.12 25.00
C. tropicalis ATCC 66029 28 ±0.05 0.05 0.10
C. tropicalis ATCC 750 19 ±0.15 0.78 12.50
C. tropicalis ATCC 13803 20 ±0.06 0.78   25.00
a MIC – Minimum Inhibitory Concentration
b MFC – Minimum Fungicidal Concentration
Inhibition zone  (mm)
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Time kill curves were performed for 3 representative
Candida spp. (C. albicans ATCC 90028, C. tropicalis ATCC
66029 and C. dubliniensis MYA-577); the killing activity
depended on time and concentrations of A. lakoocha extract.
Generally, 1× MIC could reduce the number of CFU by
approximately  50%  after  10  h  of  incubation;  however,
complete sterility was not achieved. At 4× MIC and 2× MIC,
all strains were killed after 6 and 8 h, respectively (Figure 2).
Killing by the positive control (CHX) was observed within
30 min.
The concentrations of A. lakoocha extract required to
inhibit >50% biofilm formation (MBIC50) of C. albicans ATCC
90028, C. tropicalis ATCC 66029 and C. dubliniensis MYA-
577 were 3.13±0.23, 0.39±0.12 and 0.39±0.18 mg/ml, respec-
tively, and for >90% inhibition of biofilm growth (MBIC90)
the concentrations were 25.00±0.18, 1.56±0.05, and 1.56±0.29
mg/ml, respectively. At the concentration of A. lakoocha
extract > 0.10 mg/ml, there was a statistically significant in-
hibition of biofilm growth of all tested strains compared to
non-treated control (Figure 3). The amount of A. lakoocha
extract required to eradicate >50% biofilm growth (MBEC50)
of C. albicans ATCC 90028, C. tropicalis ATCC 66029 and
C. dubliniensis MYA-577 were 6.25±0.20, 3.12±0.13 and
3.12±0.23 mg/ml, respectively, and for >90% of the eradica-
tion of biofilm growth (MBEC90) the amounts were > 25.00,
12.50±0.20 and 25.00±0.26 mg/ml, respectively. At the con-
centration of A. lakoocha extract > 0.20 mg/ml, there was a
statistically significant eradication of biofilm growth of all
tested strains compared to non-treated control (Figure 4).
4. Discussion
Candida species are the most common fungal patho-
gens in humans and are the causative agents at various loca-
tions in the body, giving rise to severe morbidity in millions
of individuals worldwide (Calderone and Fonzi, 2001; Ruhnke,
2002). In the oral cavity, C. albicans is the organism that most
frequently causes a range of mucosal infections including oral
candidiasis e.g. oropharyngeal candidiasis, angular cheilitis,
oral thrush and denture stomatitis (Richardson and Warnock,
1997; Ruhnke, 2002), NCAC have also been found dramati-
cally in oral candidal infection. The most common treatment
Figure 1. Agar  well  diffusion  assay  of  0.1%  (w/v)  A. lakoocha
extract against C. tropicalis ATCC 66029 (a) showing by
inhibition  clear  zone,  0.1  g%  (w/v)  CHX  served  as
positive control (b) and 10% (v/v) DMSO (c) served as
negative control.
Figure 2. Time kill curves of A. lakoocha extract against of C.
albicans ATCC 90028 (a), C. tropicalis ATCC 66029 (b)
and C. dubliniensis MYA-577 (c). Bacteria stains were
incubated with 0× MIC ( ), 1× MIC ( ), 2× MIC ( )
and 4× MIC ( ); 0.1% (w/v) CHX ( ) over time. CFU,
Colony Forming Units.
Figure 3. Inhibition of biofilm formation of C. albicans ATCC 90028
(a), C. tropicalis ATCC 66029 (b) and C. dubliniensis
MYA-577 (c) by A. lakoocha extract at various concentra-
tions and with 0.1% (w/v) CHX (the positive control) is
demonstrated. Error bars indicate standard deviations;
n=6. *, differences (compared to the blank control) were
considered statistically significant at P<0.05.
is the use of antifungal agents such as azoles (uconazole,
itraconazole,  miconazole  and  ketoconazole)  and  polyenes
(amphotericin B and nystatin). However, those who use such
agents are often faced with several problems including the455 S. Senapong et al. / Songklanakarin J. Sci. Technol. 36 (4), 451-457, 2014
limited number of effective antifungal agents, their high toxic-
ity and cost, the recurrence of the infection, and increasing
emergence of antifungal resistance (Klepser, 2001; Khan et
al.,  2003).  A  topical  use  of  CHX  mouthwash  is  the  most
common antimicrobial substance to control oral candidiasis.
However, CHX has been reported as having many unwanted
effects  over  long-term  use  including  unpleasant  taste  and
disturbance in taste sensation, brown discoloration of the
dorsum  of  the  tongue,  and  desquamative  lesions  of  oral
mucosa (Hiom et al., 1992; Giuliana et al., 1997).
Many  studies  have  demonstrated  that  traditional
herbs  possess  anticandidal  activity  against  Candida  spp.
(Boroujeni  et  al.,  2012;  Rukayadi  et  al.,  2006;  Yigit  et  al.,
2009). In the present study, it was found that A. lakoocha
extract has a good antifungal activity against Candida strains.
A. lakoocha has previously been reported to have antiviral
and  antibacterial  properties,  and  this  study  is  the  first  to
reveal the anticandidal activity of A. lakoocha.
In addition, A. lakoocha extract has shown antibio-
film activity. Biofilms of C. albicans and NCACs are associ-
ated with high incidence of hospital morbidity and mortality
(Nett and Andes, 2006; O’Toole et al., 2000; Silva et al.,
2010) due to the increased use of medical devices such as
lens,  implants  and  dentures.  Such  biomaterials  facilitate
Candida strains to colonize and form biofilms leading to the
development of resistance to antifungal agents, e.g. amphote-
ricin B, micronazole, ketoconazole and fluconazole (Chandra
et al., 2001; Kuriyama et al., 2005). Experiments comparing
biofilms of Candida with broth cultures have demonstrated
that  higher  concentrations  of  A. lakoocha  extract  are
required to significantly inhibit existing biofilm cells. This is
an expected result since Candida in the biofilm is strongly
protected  and  less  susceptible  to  antifungal  agents  than
Candida  in  planktonic  form  (Baillie  and  Douglas,  2000;
Chandra et al., 2012). It was shown that A. lakoocha extract
was able to remove Candida in a dose- and time- dependent
manner. Our results indicate that A. lakoocha extract acts as a
potent antibiofilm agent that has dual actions preventing
biofilm formation and removing existing biofilms.
The exact mechanism of action exerted by A. lakoocha
extract on Candida is still unclear. Among previous studies,
one study of interaction of resveratrol with Botrytis cinerea,
a  gray  mold  that  infects  grapevines,  showed  that  the
proposed mode of action involved an interference with the
functionality of membrane proteins, especially those of the
mitochondria. The interaction leads to an immediate decrease
in oxygen uptake by the fungal cells. At the ultra-structural
level, mitochondrial and nuclear membranes are affected first,
followed  by  a  complete  disorganization  of  organelles  and
disruption of the cell membrane. Another study of the effect
of A. lakoocha extract in Fasciola gigantica, a liver fluke that
causes fasciolosis, implied that A. lakoocha contains a very
high  content  of  oxyresveratrol  that  could  cause tegument
changes  by  affecting  the  oxidative  phosphorylation  in
mitochondria. It has been explained that oxyresveratrol (the
major constituent of this crude extract has similar chemical
structure to the halogenated phenol group of drugs, such as
nitroxynil) could act via a similar mechanism. It was reported
that nitroxynil acts as an uncoupler of oxidative phosphory-
lation (Fairweather et al., 1984; McKinstry et al., 2003). As a
result, the decreased production of ATP would affect the
Na
+–K
+  pump,  leading  to  the  influx  of  Na
+  and  water,  and
consequently the swelling of the syncytium as observed in
the study of F. hepatica treated with nitroxynil (McKinstry
et al., 2003).
In conclusion, the current study supports the tradi-
tional advantages of the studied plant, and suggests that the
stem  bark  A. lakoocha  extract  is  a  potential  source  as  a
natural antifungal agent. It possesses compounds with good
antifungal  properties  that  may  be  used  for  oral  infectious
diseases caused by certain Candida spp. After this screening
experiment, further work should be performed to describe the
antifungal activities in more detail as well as their activity
in vivo.
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